drugset / Trial / NCT02990091
Derivatives of Omega-3 HUFA as Biomarkers of Traumatic Brain Injury
Phase 2
Withdrawn
University of Pennsylvania
National Institute on Alcohol Abuse and Alcoholism (NIAAA) · collab
RandomizedParallel-groupSingle-blindDiagnostic
Summary
This is a Phase 2 clinical trial designed to obtain data on relationships between potentially therapeutic doses of n-3 HUFA (highly unsaturated fatty acids) and their bioactive molecular derivatives, synaptamide, 17-hydroxy-DHA, and D-series resolvins, on clinical outcomes after TBI.
Timeline
- Start
- 2017-01
- Primary completion
- 2023-01
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lovaza | Other / unclassified | 1000 mg | Oral |
| Subject | Lovaza | Other / unclassified | 4000 mg | Oral |